

# The wound area as a parameter guiding the timing of abdominal closure in the management of patients undergoing open abdominal procedures

A. SENTURK<sup>1</sup>, E. GONULLU<sup>1</sup>, Z. BAYHAN<sup>2</sup>, Y. AKDENIZ<sup>2</sup>, K. OZDEMIR<sup>1</sup>,  
B. MANTOGLU<sup>2</sup>, R. CAPOGLU<sup>1</sup>, N. FIRAT<sup>2</sup>, F. ALTINTOPRAK<sup>2</sup>

<sup>1</sup>General Surgery Department, Sakarya University Training and Research Hospital, Sakarya, Turkey

<sup>2</sup>General Surgery Department, Sakarya University Faculty of Medicine, Sakarya, Turkey

**Abstract. – OBJECTIVE:** Surgical site infections (SSI) are incomparably troublesome and complicated, and some of them require an open abdomen (OA) procedure. While deciding the timing of abdominal closure, wound area calculation method and laboratory parameters can be used to guide the timing of abdominal closure after OA procedures.

**PATIENTS AND METHODS:** The records of the patients who had undergone open abdomen during their treatment course and were followed up with vacuum-assisted closure (VAC) technique between December 2015 and December 2019 were retrospectively analyzed. The laboratory results before the first VAC application and the results after the VAC change were compared to determine a predictive parameter. The ImageJ program was used in five patients to compare the size of the wounds at the time of the decision to close them and before the first VAC application.

**RESULTS:** 102 patients were analyzed. The ratio of the last wound area to the wound area at the time of the first VAC application in five patients was 0.30, 0.41, 0.34, 0.27, 0.46 (mean: 0.36, standard deviation: 0.078) which were measured and calculated by ImageJ software.

**CONCLUSIONS:** We think that the concept of wound reduction ratio, which was calculated by a computer program, can be used as a concrete equivalent of the wound closure eligibility criteria decided by clinical experience.

## Key Words:

Open abdomen, Vacuum-assisted closure, Wound area, Computer program, ImageJ.

care conditions, but SSIs are still encountered in practice<sup>1</sup>. Despite developments in sterility, antibiotic therapy, and patient care conditions, SSIs are challenging complications to treat<sup>2</sup>.

Although the response to inflammation is systemic, fluid rich in pro-inflammatory mediators that form in the intraperitoneal area may cause inflammation to persist, with progression toward multiorgan failure<sup>3,4</sup>. Various methods have been developed to remove these pro-inflammatory mediators from the environment in patients with open abdomens (OAs)<sup>5</sup>. Regardless of the method used, however, the likelihood that complications (e.g., intraabdominal adhesions, enteroatmospheric fistulas, and fluid-electrolyte imbalance) will develop increases with the length of the follow-up period<sup>6,7</sup>. Thus, the abdomen should be closed as soon as possible in such cases<sup>8</sup>.

The literature contains no objective scale for the timing of abdominal closure, which is usually determined based on physicians' clinical experience. Methods based on the wound volume and area have been described<sup>9-11</sup>, but they have been used mainly to follow lower-extremity ulcers. No data on the application of such methods to guide the timing of abdominal closure in patients with OAs are available.

This present study aims to identify a wound area calculation method and analyze possible laboratory parameters that can be used to guide the timing of abdominal closure after OA procedures.

## Introduction

The surgical site infection (SSI) rate has declined in the past 30-40 years due to improvements in medical, surgical, and postoperative

## Patients and Methods

The Ethics Committee of the Sakarya University School of Medicine approved this study and the data collection (No. 71522473/0.50.01.04/78).

The records of patients whose management required OA procedures for any reason and who subsequently underwent vacuum-assisted closure (VAC) between December 2015 and December 2019 at the Department of General Surgery, Sakarya University Faculty of Medicine, were retrospectively analyzed. Patients who developed enteroatmospheric fistulas during the clinical follow-up period after VAC or who had significant risk factors known to affect wound healing (i.e., presence of metastatic malignancy, malnutrition, chronic steroid use, uncontrolled diabetes, recent chemotherapy and/or radiotherapy, and chronic diseases with vasculitis affecting the connective tissue) were excluded. Patients with chronic diseases or incomplete records and those who could not be reached for follow-up were also excluded. The Charlson Comorbidity Index (CCI) was used for comparison because the included patients constituted a heterogeneous group in terms of age, primary etiological cause, comorbidities, and surgical history.

A VAC system (ABThera; KCI, San Antonio, TX, USA) was used after the wounds were debrided and washed with the saline solution under operating room conditions. This system employs a 25-mm-thick polyether reticulated polyurethane hydrophobic sponge with 1.24-mm-diameter pores. It applies 500 mmHg negative pressure periodically for 5 minutes at 2-minute intervals. The VAC system was changed every 3 days unless a technical problem was encountered.

The patients' laboratory parameters and neutrophil (neu)/lymphocyte (Lym) ratio were determined before and after VAC application, and during clinical follow-up when necessary. All evaluations were performed using routinely taken blood samples; no additional blood was collected to determine laboratory parameters for this study. Laboratory results obtained before the first VAC application were defined as the baseline values, and those obtained after VAC system changes were defined as the control values.

The same surgical team evaluated all patients' wound sites visually under operating room conditions when the VAC systems were changed, and photographs were taken. Wound closure decisions were made with consideration of the patients' laboratory parameters and clinical conditions after a visual wound evaluation. Wound closures were performed one by one with non-absorbable sutures after the placement of at least one suction drain under each wound's skin flap.

A flat area of approximately 1 cm at the edge of each wound was identified. Photographs were taken vertically and from a distance of 0.5 m to cover the entire wound. The photographs were transferred to a computer. In five patients whose photograph quality was suitable to be used to calculate wound area, wound areas were calculated using ImageJ software (National Institutes of Health, Bethesda, MD, USA; <http://ImageJ.Net/ImageJ>) based on the known length of the wound edge portion. These procedures were repeated and recorded separately for each of the five patients before the first VAC application and each VAC change. For patients whose wounds were scheduled to be closed, the change in the wound area (calculated using the shrinkage rate, rather than the net wound area) and the proportion of the area in which granulation tissue had developed were determined by comparing the first and last wound parameters. The granulation tissue area was defined as a red-pink area with bleeding and minimal trauma, but no dead (black/gray/brown) tissue.

### **Statistical Analysis**

Descriptive analyses were performed to provide information on the general characteristics of the study population. Numerical variables are presented as means  $\pm$  standard deviations or medians (interquartile ranges). Categorical variables are presented as counts and percentages. *p* values  $< 0.05$  were considered to be significant. Repeated-measures analysis of variance was used to compare hematological parameters between baseline and VAC control periods. All analyses were performed using IBM SPSS Statistics software, version 23.0 (IBM Corp., Armonk, NY, USA).

### **Results**

The records of 117 patients were analyzed. One (0.8%) patient developed vasculitis (Behçet's disease), two (1.5%) patients could not be reached for follow-up, two (1.5%) patients were using chronic steroids, two (1.5%) patients had uncontrolled diabetes, five (3.9%) patients had incomplete records, and three (2.3%) patients developed grade 3-4 enteroatmospheric fistulas (according to the classification of Björck et al<sup>12</sup>; Table I) during the clinical follow-up period and were excluded from the study.

**Table I.** Björck classification of open abdomen.

| Grade | Definition   |
|-------|--|
| IA    | Clean open abdomen without adherence between the bowel and abdominal wall or fixity (lateralization of the abdominal wall) |
| IB    | Contaminated open abdomen without adherence/fixity   |
| IIA   | Clean open abdomen developing adherence/fixity   |
| IIB   | Contaminated open abdomen developing adherence/fixity  |
| III   | Open abdomen complicated by fistula formation  |
| IV    | Frozen open abdomen with adherent/fixed bowel; unable to close surgically; with or without fistula                         |

Fifty-three (52%) of the remaining 102 patients underwent surgery for reasons other than malignancy and 49 (48%) patients underwent surgery for gastrointestinal malignancy. Fifty-eight (56.8%) of the patients were females and 44 (43%) were males; their mean age was  $62.86 \pm 15.41$  years. The mean duration of hospitalization was  $22.82 \pm 22.27$  days among patients with a mean CCI of  $4.72 \pm 1.77$ . The patients' demographic characteristics are summarized in Table II.

No significant difference was found between the baseline hemoglobin (Hb) value and any control (VAC change) Hb value in any patient. No significant difference was found between the baseline and any control (VAC change) white blood cell (WBC) counts. No difference was found between the baseline neutrophil (Neu) value and any value of the control. Significant differences between baseline and control lymphocyte (Lym) values were observed for patients who underwent two ( $1.36 \text{ K}/\mu\text{L} \pm 1.09$  vs.  $2.04 \text{ K}/\mu\text{L} \pm 1.36$ ,  $p = 0.025$ ) and five ( $1.11 \text{ K}/\mu\text{L} \pm 0.57$  vs.  $1.55 \text{ K}/\mu\text{L} \pm 0.86$ ,  $p = 0.026$ ) VAC

changes, but not for those who underwent any other number of VAC changes. The baseline and control Neu/Lym ratios also differed significantly in patients who underwent two ( $8.28 \pm 7.4$  vs.  $4.3 \pm 3.44$ ,  $p = 0.014$ ) and five ( $12.43 \pm 14.19$  vs.  $8.25 \pm 10.25$ ,  $p = 0.022$ ) VAC changes, but not in other groups.

Insufficient data were available to detect differences in the C-reactive protein (CRP) and total protein values. No significant difference between the baseline and control albumin (Alb) values was observed in patients who underwent one or two VAC changes. However, these values differed significantly in patients who underwent three ( $2.83 \text{ g/L} \pm 0.34$  vs.  $3.06 \text{ g/L} \pm 0.41$ ,  $p = 0.026$ ), four ( $2.54 \text{ g/L} \pm 0.32$  vs.  $2.85 \text{ g/L} \pm 0.33$ ,  $p = 0.007$ ), and five ( $2.61 \text{ g/L} \pm 0.49$  vs.  $2.79 \text{ g/L} \pm 0.46$ ,  $p = 0.012$ ) VAC changes. No significant difference between the baseline and any control platelet (Plt) count was found in any patient (Table III).

The ratios of the last wound area to the wound area at the time of initial VAC application in the five patients whose clinical conditions were evaluated and in whom VAC application was terminated, and whose wounds were subsequently closed, were 0.30, 0.41, 0.34, 0.27, and 0.46 (mean, 0.36; standard deviation, 0.078), respectively (Figures 1-3; Table IV).

**Table II.** General characteristics of the study population.

| Patient variables                                  |                   |
|--|-------------------|
| Height (cm)  | $164.63 \pm 7.75$ |
| Weight (cm)  | $78.82 \pm 13.62$ |
| Age (year)   | $62.86 \pm 15.41$ |
| Hospitalization duration (day)                     | $22.82 \pm 22.27$ |
| Charlson comorbidity index                         | $4.72 \pm 1.77$   |
| <b>Gender</b>                                      |                   |
| Female   | 58 (56.8%)        |
| Male   | 43 (42.2%)        |
| <b>Type of surgery</b>                             |                   |
| Emergency abdominal surgery not for malignancy (n) | 39 (38.6%)        |
| Elective abdominal surgery not for malignancy (n)  | 14 (13.9%)        |
| Emergency oncological surgery (n)                  | 12 (11.9%)        |
| Elective oncological surgery (n)                   | 36 (35.6%)        |

## Discussion

The fascia ideally should be closed during the early period (the first 5-8 days) after OA procedures are performed for various reasons. When the OA period is prolonged, the inflammatory process becomes chronic and the incidence of complications, such as enteroatmospheric fistula, increases<sup>13</sup>. Thus, various temporary abdominal closure methods have been developed for situations in which the fascia cannot be closed during the early period, and different closure

**Table III.** Follow-up changes of hematological parameters according to number of VAC changes.

|                           |          | Number of VAC changes |               |               |              |                 |
|---------------------------|----------|-----------------------|---------------|---------------|--------------|-----------------|
|                           |          | 1                     | 2             | 3             | 4            | 5               |
| Albumin (g/L)             | n        | 11                    | 13            | 16            | 10           | 27              |
|                           | Baseline | 3.2 ± 0.42            | 2.6 ± 0.54    | 2.83 ± 0.34   | 2.54 ± 0.32  | 2.61 ± 0.49     |
|                           | 3. day   | 3 ± 0.49              | 2.78 ± 0.34   | 2.84 ± 0.36   | 2.81 ± 0.2   | 2.72 ± 0.44     |
|                           | 6. day   |                       | 2.79 ± 0.54   | 2.98 ± 0.34   | 2.78 ± 0.31  | 2.72 ± 0.35     |
|                           | 9. day   |                       |               | 3.06 ± 0.41   | 2.88 ± 0.27  | 2.72 ± 0.32     |
|                           | 12. day  |                       |               |               | 2.85 ± 0.33  | 2.88 ± 0.41     |
|                           | 15. day  |                       |               |               |              | 2.79 ± 0.46     |
|                           | p        | 0.71                  | 0.317         | 0.026         | 0.007        | 0.012           |
|                           | adj-p*   | 0.484                 | 0.656         | 0.675         | 0.645        | 0.023           |
| C-reactive protein (mg/L) | n        | 3                     | 3             | 6             | 1            | 4               |
|                           | Baseline | 23 ± 19.67            | 24.71 ± 19.72 | 61.97 ± 40.63 | 124          | 209.75 ± 152.68 |
|                           | 3. day   | 18.11 ± 20.99         | 8.32 ± 4.84   | 34.85 ± 15.5  | 87.4         | 89.7 ± 8.37     |
|                           | 6. day   |                       | 4.78 ± 1.84   | 24.64 ± 23.42 | 23.8         | 93.1 ± 26.2     |
|                           | 9. day   |                       |               | 30.78 ± 29.04 | 20.3         | 88.5 ± 33.47    |
|                           | 12. day  |                       |               |               | 9.97         | 52.43 ± 24.3    |
|                           | 15. day  |                       |               |               |              | 39.75 ± 33.03   |
|                           | p        |                       |               |               |              |                 |
|                           | adj-p*   |                       |               |               |              |                 |
| Hemoglobin (g/dL)         | n        | 13                    | 21            | 20            | 16           | 30              |
|                           | Baseline | 11 ± 2.09             | 10.54 ± 1.61  | 10.52 ± 1.19  | 9.74 ± 1.36  | 9.83 ± 1.66     |
|                           | 3. day   | 10.75 ± 1.3           | 10.64 ± 1.17  | 10.53 ± 1.34  | 10.14 ± 0.88 | 10.12 ± 1.17    |
|                           | 6. day   |                       | 10.32 ± 1.35  | 10.43 ± 1.21  | 10.59 ± 1.92 | 10.38 ± 1.14    |
|                           | 9. day   |                       |               | 10.58 ± 1.36  | 9.96 ± 1.02  | 10.02 ± 1.06    |
|                           | 12. day  |                       |               |               | 10.26 ± 1.04 | 9.99 ± 1.15     |
|                           | 15. day  |                       |               |               | 10.02 ± 1.01 |                 |
|                           | p        | 0.549                 | 0.308         | 0.842         | 0.604        | 0.103           |
|                           | adj-p*   | 0.077                 | 0.723         | 0.402         | 0.172        | 0.787           |
| Lymphocyte (K/μL)         | n        | 13                    | 21            | 19            | 16           | 30              |
|                           | Baseline | 1.96 ± 0.85           | 1.36 ± 1.09   | 1.43 ± 0.65   | 1.12 ± 0.83  | 1.11 ± 0.57     |
|                           | 3. day   | 2.12 ± 1.03           | 1.63 ± 1.14   | 1.61 ± 0.73   | 1.82 ± 1.48  | 1.36 ± 0.67     |
|                           | 6. day   |                       | 2.04 ± 1.36   | 1.74 ± 0.89   | 1.55 ± 1.11  | 1.89 ± 1.64     |
|                           | 9. day   |                       |               | 1.85 ± 0.93   | 1.53 ± 0.92  | 1.61 ± 0.83     |
|                           | 12. day  |                       |               |               | 1.55 ± 0.98  | 1.66 ± 0.87     |
|                           | 15. day  |                       |               |               |              | 1.55 ± 0.86     |
|                           | p        | 0.233                 | 0.025         | 0.239         | 0.196        | 0.026           |
|                           | adj-p*   | 0.388                 | 0.21          | 0.47          | 0.134        | 0.389           |
| MPV (fl)                  | n        | 13                    | 19            | 20            | 14           | 28              |
|                           | Baseline | 7.25 ± 0.79           | 8.33 ± 1.48   | 8.07 ± 0.86   | 8.81 ± 1.44  | 8.49 ± 1.92     |
|                           | 3. day   | 7.57 ± 1.33           | 8.23 ± 1.2    | 7.99 ± 1.07   | 8.09 ± 1.33  | 8.01 ± 1.8      |
|                           | 6. day   |                       | 8.08 ± 1.44   | 7.9 ± 1.17    | 7.92 ± 1.22  | 8.27 ± 2.67     |
|                           | 9. day   |                       |               | 7.94 ± 1.19   | 8.1 ± 1.55   | 7.96 ± 1.67     |
|                           | 12. day  |                       |               |               | 8.23 ± 1.78  | 7.93 ± 2        |
|                           | 15. day  |                       |               |               |              | 8.11 ± 2.23     |
|                           | p        | 0.263                 | 0.768         | 0.824         | 0.091        | 0.132           |
|                           | adj-p*   | 0.144                 | 0.954         | 0.91          | 0.979        | 0.769           |
| Neutrophil (K/μL)         | n        | 13                    | 21            | 20            | 16           | 30              |
|                           | Baseline | 7.08 ± 5.1            | 6.8 ± 2.99    | 7.21 ± 3.38   | 8.41 ± 4.69  | 8.77 ± 4.45     |
|                           | 3. day   | 5.09 ± 2.39           | 6.68 ± 4.16   | 6.49 ± 2.48   | 9.5 ± 4.26   | 9.15 ± 5.3      |
|                           | 6. day   |                       | 5.92 ± 3.04   | 6.19 ± 2.63   | 7.09 ± 3.08  | 8.71 ± 4.03     |
|                           | 9. day   |                       |               | 7.17 ± 3.5    | 7.99 ± 4.23  | 7.75 ± 4.36     |
|                           | 12. day  |                       |               |               | 8.16 ± 6.21  | 7.94 ± 6.95     |
|                           | 15. day  |                       |               |               |              | 8.72 ± 11.17    |
|                           | p        | 0.079                 | 0.514         | 0.609         | 0.312        | 0.346           |
|                           | adj-p*   | 0.343                 | 0.963         | 0.147         | 0.944        | 0.6             |

Continued




## Wound area evaluation in open abdomen

**Table III (Continued).** Follow-up changes of hematological parameters according to number of VAC changes.

|                         |                 | Number of VAC changes |                 |                 |                 |                 |
|-------------------------|-----------------|-----------------------|-----------------|-----------------|-----------------|-----------------|
|                         |                 | 1                     | 2               | 3               | 4               | 5               |
| Neu/lym ratio           | n               | 13                    | 21              | 19              | 16              | 30              |
|                         | Baseline        | 3.76 ± 1.95           | 8.28 ± 7.4      | 6.46 ± 5.04     | 15.76 ± 20.19   | 12.43 ± 14.19   |
|                         | 3. day          | 4.67 ± 8.64           | 9.12 ± 14.31    | 5.29 ± 4.51     | 10.68 ± 14.77   | 9.02 ± 7.53     |
|                         | 6. day          |                       | 4.3 ± 3.44      | 4.56 ± 3.69     | 7.52 ± 6.49     | 7.09 ± 5.21     |
|                         | 9. day          |                       |                 | 6.7 ± 9.62      | 7.43 ± 5.43     | 5.97 ± 4.55     |
|                         | 12. day         |                       |                 |                 | 11.5 ± 14.6     | 6.26 ± 5.95     |
|                         | 15. day         |                       |                 |                 |                 | 8.25 ± 10.25    |
|                         | <i>p</i>        | 0.68                  | 0.014           | 0.071           | 0.307           | 0.022           |
|                         | adj- <i>p</i> * | 0.469                 | 0.544           | 0.626           | 0.464           | 0.783           |
| Platelet (K/μL)         | n               | 13                    | 21              | 20              | 16              | 31              |
|                         | Baseline        | 309.08 ± 103.31       | 261.65 ± 104.08 | 306.5 ± 125.51  | 269.56 ± 93.43  | 304.37 ± 169.93 |
|                         | 3. day          | 274.54 ± 72.94        | 287.3 ± 149.26  | 366.25 ± 147.85 | 292.73 ± 112.69 | 309.86 ± 173.83 |
|                         | 6. day          |                       | 312.19 ± 170.36 | 400.8 ± 184.14  | 359.03 ± 205.92 | 328.28 ± 173.07 |
|                         | 9. day          |                       |                 | 335.28 ± 150.17 | 300.41 ± 123.54 | 333.66 ± 168.64 |
|                         | 12. day         |                       |                 |                 | 292.94 ± 143.1  | 327.76 ± 172.06 |
|                         | 15. day         |                       |                 |                 |                 | 317.28 ± 204.79 |
|                         | <i>p</i>        | 0.096                 | 0.109           | 0.098           | 0.427           | 0.803           |
|                         | adj- <i>p</i> * | 0.782                 | 0.203           | 0.35            | 0.34            | 0.305           |
| Total protein (g/L)     | n               | 2                     | 2               | 1               |                 |                 |
|                         | Baseline        | 5.8 ± 0.14            | 5.15 ± 2.47     | 6.8             |                 |                 |
|                         | 3. day          | 6.15 ± 0.35           | 5.55 ± 3.18     | 6.4             |                 |                 |
|                         | 6. day          |                       | 5.35 ± 2.9      | 7               |                 |                 |
|                         | 9. day          |                       |                 | 7.9             |                 |                 |
|                         | 12. day         |                       |                 |                 |                 |                 |
|                         | 15. day         |                       |                 |                 |                 |                 |
| <i>p</i>                |                 |                       |                 |                 |                 |                 |
| adj- <i>p</i> *         |                 |                       |                 |                 |                 |                 |
| White blood cell (K/μL) | n               | 13                    | 21              | 20              | 16              |                 |
|                         | Baseline        | 10.06 ± 5.78          | 9.09 ± 3.95     | 9.64 ± 3.41     | 10.35 ± 4.85    | 11.24 ± 5.52    |
|                         | 3. day          | 8.09 ± 3.15           | 9.06 ± 3.94     | 9.1 ± 2.86      | 11.98 ± 4.28    | 12 ± 6.28       |

\*adj-*p*: Adjusted *p*-value: the *p*-value calculated by the Bonferroni method to eliminate type 1 error for the *p*-value determined by statistical methods. Mean Platelet Volume (MPV), vacuum-assisted closure (VAC).



**Figure 1.** First VAC application of patient 1.

rates have been reported<sup>7,8</sup>. Methods such as skin closure and the Bogota bag application, which were very common historically, are still used today, but VAC systems are increasingly applied. In a study<sup>14</sup> of 239 patients, the rate of primary fascia closure was higher in patients who had undergone skin closure alone than in those who had undergone other procedures, but this method was preferred for patients with lower trauma scores; VAC application was preferred for patients who underwent damage-control surgery and had more severe trauma. In another study<sup>15</sup>, the rate of primary fascia closure after VAC application was 31%. Apart from abdominal closure, VAC systems are useful for the evacuation of exudate from the wound area, reduction of edema, increase in tissue oxygenation, reduction of the bacterial load, increase in angiogenesis *via* increases




Figure 2. Mid-treatment of patient 1.




Figure 3. Before the wound closure of patient 1.

in the local concentrations of interleukin-8 and vascular endothelial growth factor, and acceleration of granulation tissue development and wound contraction<sup>16,17</sup>. In our clinic, VAC application is the first choice for patients who undergo OA procedures; skin closure or Bogota bag application is performed only when a VAC system cannot be used for various technical reasons.

The WBC count is a useful parameter for the prediction of prognosis and mortality in many clinical situations, such as in the context of acute coronary syndrome, acute cerebral ischemia, or acute appendicitis, and for the prediction of kidney loss in patients with diabetes mellitus<sup>18-21</sup>.

The Neu/Lym ratio, mean Plt volume, Plt number, and Hb, Alb, and CRP concentrations are among the parameters whose predictive ability in various clinical situations has been investigated<sup>22-29</sup>. These parameters have been used to predict mortality in patients with pneumonia, the progression of various gastrointestinal malignancies, and the activation of ulcerative colitis and to diagnose testicular torsion. In our study, the significant differences found between groups of patients who underwent different numbers of VAC changes could not be used to predict the number of VAC changes or to determine the timing of abdominal closure because the patients in

Table IV. Wound area calculation by using the ImageJ.

| Patient | First VAC application (cm <sup>2</sup> ) | In the middle of the treatment process (cm <sup>2</sup> ) | Before wound closure (cm <sup>2</sup> ) | The ratio of the latest area of the wound to the first area calculated before treatment (cm <sup>2</sup> ) |
|---------|--|---|---|--|
| 1       | 80.108                                   | 46.016  | 23.836                                  | 0.30   |
| 2       | 89.607                                   | 52.512  | 36.738                                  | 0.41   |
| 3       | 35.403                                   | 28.104  | 12.038                                  | 0.34   |
| 4       | 51.798                                   | 36.048  | 13.985                                  | 0.27   |
| 5       | 45.529                                   | 41.314  | 20.488                                  | 0.46   |

our study had OAs and thus were quite different from those included in other studies in which these parameters were evaluated. These parameters have generally been used to determine the presence or absence of single clinical conditions or to predict prognosis. In contrast, patients with OAs have more than one clinical issue that requires follow-up in an intensive care setting. Moreover, maintenance processes performed in these patients can be quite long and include blood and blood product (e.g., thrombocyte and Alb) transfusion. Thus, these laboratory parameters may not be useful for the evaluation of the degree of wound healing.

The absence of peritonitis, the sufficiency of the abdominal domain after fascia closure and the absence of visceral edema should be considered when making decisions about fascia closure<sup>13,30</sup>. In our clinic, the decision to terminate VAC and close a patient's OA is made after systemic investigation for sepsis, determination that the abdominal domain is sufficient, and consideration of granulation tissue development and the wound reduction rate. Thus, the decision is based on clinical experience.

Wound area calculation using computer programs and medical treatments for open wounds have been described in the literature, and positive results have been reported. However, the results reported<sup>31,32</sup> for wound area measurement have been limited to the nonsurgical maintenance of open wounds (i.e., diabetic ulcers, pressure sores, and those caused by venous obstruction); no data on the use of this method in patients with OAs are available. With this method, wounds are evaluated according to evidence-based medicine. Treatment effectiveness is observed and recorded objectively, and this method enables easy comparison of the same types of wound<sup>33</sup>. However, the calculation of wound area entails a certain amount (10-44%) of error. Methods such as digital planimetry and the use of three-dimensional cameras have been developed to reduce this margin of error<sup>11,31</sup>, but their application in patients with OAs during all VAC changes does not seem to be convenient in terms of cost and sterility requirements. Photographs can be transferred easily to the ImageJ program, and the ratio of reduction from the initial wound state can be determined by measuring the wound area. The advantages of this method are that it entails no additional cost, that many images can be obtained, and the most appropriate ones can be selected. Most importantly, errors made in area calculation are negligible, as we

use the shrinkage rate instead of the net wound area. However, clinical decision-making cannot rely on artificial intelligence. Clinical experience, treatment and care opportunities of the medical facility, patient conditions such as co-morbidities and immune status, and pathophysiology of the wound and infection should also be evaluated. As the use of computerized systems and artificial intelligence is gradually increasing in all fields of life, it is inevitable that they will be used in the medical field. However, the integration of such systems will be easier and more efficient when patient and disease factors are adopted into the algorithms of the computer systems. In the design of such interpretive technological algorithms or systems, objective measurements are the most dependable variables. On the other hand, the individuality of the patient and the uniqueness of the disease should never be underestimated<sup>34-36</sup>. From this point of view, the major limitation of scientific research is the question of whether other variables related to the patient and disease are not included in the algorithm. Another limitation of this study is that the study is retrospective; therefore, photographs in which the area measurement can be made in a reliable way could be obtained in a small number of patients.

## Conclusions

The concept of a wound reduction ratio calculated using a computer program may be in the early days, and yet, it cannot replace the wound closure eligibility criteria determined by clinical experience. However, it is very promising, and if patient and disease factors are adopted into the algorithm, it may be a useful tool for clinical decision-making.

---

### Conflict of Interest

The authors declare that they have no conflict of interests.

---

### Funding

This research received no external funding.

---

### Informed Consent

The data of patients are obtained from our patients anonymously. Informed consent was obtained from all patients. The data does not contain sensitive data. All authors signed informed consent when enrolled in the hospital.



### Ethics Approval

This study was approved by the Faculty of Medicine, Sakarya University. Ethics Committee approval No: 71522473/0.50.01.04/78.

### Authors' Contribution

AS, EG: study concept and design, acquisition of data, analysis and interpretation of data, drafting and revision of the article, final approval for the submission. ZB: acquisition of data, drafting and revision of the article, final approval for the submission. YA: acquisition of data, drafting and revision of the article, final approval for the submission. KO: acquisition of data, critical revision of the article, final approval for the submission. BM: acquisition of data, revision of the article, final approval for the submission. RC: acquisition of data, revision of the article, final approval for the submission. NF: acquisition of data, revision of the article, final approval for the submission. FA: acquisition of data, revision of the article, final approval for the submission.

### References

- 1) Bashaw MA, Keister KJ. Perioperative strategies for surgical site infection prevention. *AORN J* 2019; 109: 68-78.
- 2) Young PY, Khadaroo RG. Surgical site infections. *Surg Clin North Am* 2014; 94: 1245-1264.
- 3) Holzheimer RG, Schein M, Wittmann DH. Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. *Arch Surg* 1995; 130: 1314-1320.
- 4) Roberts DJ, Jenne CN, Ball CG, Tiruta C, Léger C, Xiao Z, Faris PD, Mcbeth PB, Doig CJ, Skinner CR, Ruddell SG, Kubes P, Kirkpatrick AW. Efficacy and safety of active negative pressure peritoneal therapy for reducing the systemic inflammatory response after damage control laparotomy (the intra-peritoneal vacuum trial): study protocol for a randomized controlled trial. *Trials* 2013; 14: 141.
- 5) Ribeiro MA Jr, Barros EA, Carvalho SM, Nascimento VP, Cruvinel J Neto, Fonseca AZ. Comparative study of abdominal cavity temporary closure techniques for damage control. *Rev Col Bras Cir* 2016; 43: 368-373.
- 6) Kaplan M, Banwell P, Orgill D, Ivatury R, Demetriades D, Moore, FA, Miller, P, Nicholas J, Henry S. Guidelines for the management of the open abdomen. *Wounds* 2005; 17: 1-24.
- 7) Cheatham ML, Demetriades D, Fabian TC, Kaplan MJ, Miles WS, Schreiber MA, Holcomb JB, Bochicchio G, Sarani B, Rotondo MF. Prospective study examining clinical outcomes associated with a negative pressure wound therapy system and barker's vacuum packing technique. *World J Surg* 2013; 37: 2018-2030.
- 8) Regner JL, Kobayashi L, Coimbra R. Surgical strategies for management of the open abdomen. *World J Surg* 2012; 36: 497-510.
- 9) Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, Lesser M, Widmann WD. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. *Pancreatology* 2011; 11: 445-452.
- 10) Tanrikulu Y. Diagnostic utility of the neutrophil-to-lymphocyte ratio in patients with acute mesenteric ischemia: a retrospective cohort study. *Ulus Travma Acil Cerrahi Derg* 2016; 22: 344-349.
- 11) Williams KJ, Sounderajah V, Dharmarajah B, Thapar A, Davies AH. Simulated wound assessment using digital planimetry versus three-dimensional cameras: implications for clinical assessment. *Ann Vasc Surg* 2017; 41: 235-240.
- 12) Björck M, Bruhin A, Cheatham M, Hinck D, Kaplan M, Manca G, Wild T. Classification--important step to improve management of patients with an open abdomen. *World J Surg* 2009; 33: 1154-1157.
- 13) Miller RS, Morris JA Jr, Diaz JJ Jr, Herring MB, May AK. Complications after 344 damage-control open celiotomies. *J Trauma* 2005; 59: 1365-1374.
- 14) Hu P, Uhlich R, Gleason F, Kerby J, Bosarge P. Impact of initial temporary abdominal closure in damage control surgery: a retrospective analysis. *World J Emerg Surg* 2018; 13: 43.
- 15) Bee TK, Croce MA, Magnotti LJ, Zarzaur BL, Maish GO3rd, Minard G, Schroepel TJ, Fabian TC. Temporary abdominal closure techniques: a prospective randomized trial comparing polyglactin 910 mesh and vacuum-assisted closure. *J Trauma* 2008; 65: 337-344.
- 16) Agarwal P, Kukrele R, Sharma D. Vacuum assisted closure (vac)/negative pressure wound therapy (npwt) for difficult wounds: a review. *J Clin Orthop Trauma* 2019; 10: 845-848.
- 17) Wang W, Pan Z, Hu X, Li Z, Zhao Y, Yu AX. Vacuum-assisted closure increases icam-1, mif, vegf and collagen i expression in wound therapy. *Exp Ther Med* 2014; 7: 1221-1226.
- 18) Aydin OU, Soyulu L, Dandin O, Uysal Aydin E, Karademir S. Laboratory in complicated appendicitis prediction and predictive value of monitoring. *Bratislava Med J* 2016; 12: 697-701.
- 19) Zhang C, Liu H, Wang H, Tao Q, Lin X, Ge S, Zhai Z. The predictive value of potential hematological biomarkers in acute coronary syndrome. *Clin Lab* 2019; 65: 10.
- 20) You S, Ou Z, Zhang W, Zheng D, Zhong C, Dong X, Qiu C, Lu T, Cao Y, Liu CF. Combined utility of white blood cell count and blood glucose for predicting in-hospital outcomes in acute ischemic stroke. *J Neuroinflammation* 2019; 16: 37.
- 21) Wheelock KM, Saulnier PJ, Tanamas SK, Vijayakumar P, Weil EJ, Looker HC, Hanson RL, Lemley KV, Yee B, Knowler WC, Hadjadj S, Najafian B, Mauer M, Nelson RG. White blood cell fractions correlate with lesions of diabetic kidney disease and predict loss of kidney function in type 2 diabetes. *Nephrol Dial Transplant* 2018; 6: 1001-1009.



- 22) Kim NY, Chun DH, Kim SY, Kim NK, Baik SH, Hong JH, Kim KS, Shin CS. Prognostic value of systemic inflammatory indices, nlr, plr, and mpv, for predicting 1-year survival of patients undergoing cytoreductive surgery with hipec. *J Clin Med* 2019; 8: 589.
- 23) Liang H, Gao Y, Miao C, Song Y, He F. Predictive value of neutrophil to lymphocyte ratio on 28-day mortality of patients with severe pneumonia. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2019; 31: 827-831.
- 24) Jiang C, Liu C, Guo J, Chen L, Luo N, Qu X, Yang W, Ren Q, Cheng Z. Ca125 modified by plt and nlr improves the predictive accuracy of adenyosis-derived pelvic dense adhesion. *Medicine (Baltimore)* 2017; 96: E6880.
- 25) Zhu J, Song Y, Chen G, Hu R, Ou N, Zhang W, Liang Z, Liu X. Predictive value of haematologic parameters in diagnosis of testicular torsion: evidence from a systematic review and meta-analysis. *Andrologia* 2020; 52: E13490.
- 26) Ibarra-Rodríguez JJ, Santiago-Luna E, Velázquez-Ramírez GA, López-Ramírez MK, Fuentes-Orozco C, Cortés-Flores AO, González-Ojeda A. Sensitivity, specificity, and predictive values of the level of hemoglobin, hematocrit and platelet count as an activity index in ulcerative colitis. *Cir Cir* 2005; 5: 355-362.
- 27) Arques, S. Serum albumin and cardiovascular diseases: a comprehensive review of the literature. *Ann Cardiol Angeiol (Paris)* 2018; 67: 82-90.
- 28) Shafaghi A, Gharibpoor F, Mahdipour Z, Samadani AA. Comparison of three risk scores to predict outcomes in upper gastrointestinal bleeding; modifying glasgow-blatchford with albumin. *Rom J Intern Med* 2019; 57: 322-333.
- 29) Kaplan M, Ates I, Akpınar MY, Yuksel M, Kuzu UB, Kacar S, Coskun O, Kayacetin E. Predictive value of c-reactive protein/albumin ratio in acute pancreatitis. *Hepatobiliary Pancreat Dis Int* 2017; 16: 424-430.
- 30) Lambertz A, Mihatsch C, Röth A, Kalverkamp S, Eickhoff R, Neumann UP, Klink CD, Junge K. Fascial closure after open abdomen: initial indication and early revisions are decisive factors--a retrospective cohort study. *Int J Surg* 2015; 13: 12-16.
- 31) Chang AC, Dearman B, Greenwood JE. A comparison of wound area measurement techniques: visitrak versus photography. *Eplasty* 2011; 11: E18.
- 32) Aragón-Sánchez J, Quintana-Marrero Y, Aragón-Hernández C, Hernández-Herero MJ. Imagej: a free, easy, and reliable method to measure leg ulcers using digital pictures. *Int J Low Extrem Wounds* 2017; 16: 269-273.
- 33) Rennert R, Golinko M, Kaplan D, Flattau A, Brem H. Standardization of wound photography using the wound electronic medical record. *Adv Skin Wound Care* 2009; 22: 32-38.
- 34) Basile G, Gallina M, Passeri A, Gaudio RM, Castelnovo N, Ferrante P, Calori GM. Prosthetic joint infections and legal disputes: a threat to the future of prosthetic orthopedics. *J Orthop Traumatol* 2021; 22: 44.
- 35) Gullo G, Scaglione M, Buzzaccarini G, Laganà AS, Basile G, Chiantera V, Cucinella G, Zaami S. Cell-free fetal dna and non-invasive prenatal diagnosis of chromosomopathies and pediatric monogenic diseases: a critical appraisal and medicolegal remarks. *J Pers Med* 2023; 13: 1.
- 36) Oliva A, Grassi S, Zedda M, Dionigi G, Makay O, Filograna L, Cazzato F, De Crea C, Celik S, Spagnolo AG, Bellantone R, Raffaelli M. Ethical and medico-legal issues of TOETVA procedure and simulation on cadavers: a scoping review. *Eur Rev Med Pharmacol Sci* 2022; 26: 4550-4556.